News
Prescient secures OmniCAR cell lines for upcoming clinical trials
Prescient has entered a deal with the manufacturing arm of the world-renowned QIMR Berghofer Medical Research Institute in Brisbane to advance clinical trials of its…
Article, News
Prescient Therapeutics (ASX:PTX) locks in OmniCAR cell manufacturing contract for clinical trials
Prescient Therapeutics (PTX) has signed a manufacturing services agreement with Q-Gen Cell Therapeutics to produce its OmniCAR cell lines for its upcoming clinical trials.
News
Prescient Therapeutics sures supply of cell therapeutic in the hopes of commencing clinical trials
During the second World War, scientists noted that soldiers exposed to nitrogen mustard gas developed interesting hematologic pathology with significantly reduced white blood cell counts….
News
Prescient Therapeutics enters into OmniCAR cell production agreement with Q-Gen Cell
Q-Gen Cell will produce and deliver the OmniCAR cell lines from its Brisbane facility to be used for Prescient’s upcoming clinical trials.
News
Prescient Therapeutics signs deal with Q-Gen to enable OmniCAR clinical trials
Clinical-stage oncology company Prescient Therapeutics (ASX: PTX) has entered a services agreement with specialist cell therapy manufacturer Q-Gen Cell Therapeutics for the manufacture of its OmniCAR cell…
News
Prescient Therapeutics (ASX: PTX) – Webinar Presentation
Steven Yatomi-Clarke – CEO & MD – Prescient Therapeutics is focused on developing novel, personalised therapies for a range of cancers.
News
The companies aiming to beat cancer serve up the highlights in the June quarter
Precedence Research suggests the global cancer therapeutics market size is predicted to surpass US$365.99 billion by 2030 and expand growth at a CAGR of 9.1%…
News
Challenging the pace of change in healthcare: Prescient Therapeutics
“The fact of the matter is there are people walking around now who shouldn’t be alive, but they are because of our trials, which is…
News
Prescient (ASX: PTX) makes ‘solid progress on all fronts’ in June quarter
Clinical-stage oncology company Prescient Therapeutics Limited (ASX: PTX) has provided an upbeat update for the June 2022 quarter, which saw ‘solid progress on all fronts’. The ASX-listed…
News
ASX Quarterlies: From fintech to biotech, these small caps have delivered strong performances for shareholders
It’s quarterlies season as the ASX market announcements page becomes increasingly flooded with lodgements. The last day for companies to submit reports is the last…